Markets and distributes advanced medical imaging and neurosurgical technologies through subsidiaries and associates. Its wholly-owned subsidiary Time Medical International Ventures (India) supplies MRI systems, intraoperative MRI suites (including the AI-enabled DRIS-iMRI Medharanya Suite for neurosurgery combining AR, AI, ML and Exoscope technologies), Exoscope systems, and brain aneurysm screening solutions. Through associate Nanomedic Technologies, it holds exclusive India and Southeast Asia distribution rights for the Spincare portable electrospun wound care system, which received CDSCO import approval as India's first such clearance for a portable electrospun wound care device. The company operates as a single reportable segment under Ind AS 108, and reported FY26 revenue of Rs. 308.58 crore with net profit of Rs. 31.02 crore. A partnership with the WFNS Innovation & Technology Committee, the first such formal industry tie-up in the committee's history, supports global training and knowledge-sharing in neurosurgical technologies. On the cost side, materials account for 20.2% of revenue and other operating expenses for 34.9%, with employee cost at 4.9% and depreciation at 1.0%. A Rs. 358.46 crore preferential issue has funded imaging technology growth and general corporate purposes, with Rs. 280.93 crore deployed by March 2026. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Medical imaging and neurosurgical technology (consolidated, single reportable segment). Niche medical technology distribution and clinical partnership business in advanced imaging and wound care.
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 21 | 111 | 309 |
| EBITDA (ex other income) | 2 | 3 | 43 |
| margin % | 8.9 | 2.6 | 14.0 |
| Owners' profit | 2 | 1 | 31 |
| EPS, as reported (₹) | 1.65 | 0.22 | 0.48 |
| ROE % · ROCE % | 2.3 · 2.6 | 0.4 · 0.7 | 8.1 · 12.7 |
| Debt / equity (x) | 0.02 | 0.18 | 0.19 |
| Cash from operations | 2 | (86) | (101) |
| Capex | (0) | (6) | (1) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 12 | 49 | 23 | 86 | 101 | 98 | 82 |
| Profit before tax | 0 | 0 | 2 | 10 | 17 | 21 | (2) | 8 |
| Net profit | 0 | (0) | 1 | 5 | 14 | 19 | (7) | 4 |
| EPS (₹) | 0.05 | (0.05) | 0.09 | 0.77 | 2.15 | 0.30 | (0.11) | 0.06 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L ◆ | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Newspaper ad published for AGM Notice and Annual Report dispatch | compliance | minimal | — | — |
| 7 Sept 2026 · Fischer Medical files BRSR report for FY 2025-26 | compliance | minimal | — | — |
| 7 Sept 2026 · Fischer Medical Ventures files FY25-26 Annual Report | compliance | low | — | — |
| 7 Sept 2026 · 33rd AGM scheduled for September 29, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 7 Sept 2026 · FMV shares investor presentation ahead of analyst call on Sept 7, 2026 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Pre-dispatch notice for AGM 2026 published in newspapers | compliance | minimal | — | — |
| 4 Sept 2026 · Fischer Medical Ventures schedules analyst or investor meet on Sept 7, 2026 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Dividend and e-voting record date set for September 22, 2026 | corporate actions | high | — | — |
| 3 Sept 2026 · Independent Director appointed, 33rd AGM set for Sep 29 | management changes | medium | — | — |
| 28 Aug 2026 · Subsidiary TMIV Imaging launches AI-driven CLARION CT system in India | business updates | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| FABTECH TECHNOLOGIES LTD |
| 650 |
| 10.6 |
| 1.55 |
| 10.6 |
| 9.1 |
| 10.7 |
| — |
| 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 15.0 | 20.0 | 6 of 17 | 69% |
| P/B | 6.1 | 2.7 | 11 of 11 | 0% |
| ROCE | 11.3 | 11.3 | 9 of 17 | 50% |
| ROE | 8.1 | 8.1 | 6 of 11 | 50% |
| Debt / Equity | 0.2 | 0.1 | 8 of 11 | 30% |
| EBITDA margin | 15.6 | 16.7 | 7 of 11 | 40% |
| Revenue growth | 249.4 | 13.9 | 1 of 13 | 100% |
| Profit growth | (24.3) | 75.5 | 9 of 10 | 11% |
| Market cap | 2353 | 175 | 2 of 17 | 94% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
